1. Home
  2. CRSP vs TDS Comparison

CRSP vs TDS Comparison

Compare CRSP & TDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$53.57

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Telephone and Data Systems Inc.

TDS

Telephone and Data Systems Inc.

HOLD

Current Price

$44.93

Market Cap

5.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
TDS
Founded
2013
1968
Country
Switzerland
United States
Employees
N/A
4000
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.1B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
TDS
Price
$53.57
$44.93
Analyst Decision
Buy
Strong Buy
Analyst Count
17
3
Target Price
$70.29
$53.33
AVG Volume (30 Days)
1.6M
580.8K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
0.36%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$807.72
$4.05
Revenue Next Year
$172.52
$1.72
P/E Ratio
N/A
N/A
Revenue Growth
9169.85
N/A
52 Week Low
$33.03
$31.07
52 Week High
$78.48
$47.80

Technical Indicators

Market Signals
Indicator
CRSP
TDS
Relative Strength Index (RSI) 52.63 50.54
Support Level $50.91 $43.02
Resistance Level $60.45 $45.02
Average True Range (ATR) 2.72 1.08
MACD -0.31 -0.07
Stochastic Oscillator 42.74 33.88

Price Performance

Historical Comparison
CRSP
TDS

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TDS Telephone and Data Systems Inc.

Telephone and Data Systems Inc is a diversified telecommunications operator that provides communications services to customers through broadband, video, voice, and wireless connections. The company has two reportable segments: TDS Telecom and Array. The majority of its revenue is generated from the TDS Telecom segment, which generates revenue by providing broadband, video, voice, and wireless services. The Array segment generates its revenue mainly by leasing tower space on Array-owned towers to customers.

Share on Social Networks: